Prognostic factors for disease progression and CLL-related death in multivariate Cox regression
Factor . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| All stages, EFS for all stages | ||
| Model 1 including IGVH | ||
| Age | 1.1 (1.0-1.2) | .20* |
| Sex, male | 1.4 (1.0-2.0) | .29 |
| Binet stage B/C | 2.6 (1.8-3.7) | .01 |
| UM IGVH | 5.0 (3.4-7.2) | <.001 |
| Model 2 including L/A ratib† | ||
| Age | 1.1 (1.0-1.2) | .50* |
| Sex, male | 1.4 (1.2-2.7) | .12 |
| Binet stage B/C | 2.5 (1.7-3.7) | .02 |
| L/A ratio 1 or greater | 5.6 (3.8-8.1) | <.001 |
| EFS for Binet stage A | ||
| Model 1 including IGVH | ||
| Age | 1.0 (0.9-1.1) | .86* |
| Sex, male | 1.6 (1.0-2.3) | .28 |
| UM IGVH | 5.7 (3.6-9.1) | <.001 |
| Model 2 including L/A ratio and ZAP-70 | ||
| Age | 0.9 (0.8-1.0) | .29* |
| Sex, male | 1.7 (1.0-2.7) | .32 |
| ZAP-70 greater than 20% | 4.2 (2.3-7.7) | .02 |
| L/A ratio 1 or greater | 3.9 (2.1-7.2) | .03 |
| OS for stages B and C | ||
| Model 1 including IGVH | ||
| Age | 1.5 (1.2-1.8) | .03* |
| Sex, male | 1.0 (0.5-2.1) | .99 |
| UM IGVH | 7.2 (3.4-15.1) | .01 |
| Model 2 including L/A ratio† | ||
| Age | 1.6 (1.3-2.0) | .05* |
| Sex, male | 0.5 (0.3-1.3) | .46 |
| L/A ratio 1 or greater | 6.8 (3.3-14) | .01 |
Factor . | Hazard ratio (95% CI) . | P . |
|---|---|---|
| All stages, EFS for all stages | ||
| Model 1 including IGVH | ||
| Age | 1.1 (1.0-1.2) | .20* |
| Sex, male | 1.4 (1.0-2.0) | .29 |
| Binet stage B/C | 2.6 (1.8-3.7) | .01 |
| UM IGVH | 5.0 (3.4-7.2) | <.001 |
| Model 2 including L/A ratib† | ||
| Age | 1.1 (1.0-1.2) | .50* |
| Sex, male | 1.4 (1.2-2.7) | .12 |
| Binet stage B/C | 2.5 (1.7-3.7) | .02 |
| L/A ratio 1 or greater | 5.6 (3.8-8.1) | <.001 |
| EFS for Binet stage A | ||
| Model 1 including IGVH | ||
| Age | 1.0 (0.9-1.1) | .86* |
| Sex, male | 1.6 (1.0-2.3) | .28 |
| UM IGVH | 5.7 (3.6-9.1) | <.001 |
| Model 2 including L/A ratio and ZAP-70 | ||
| Age | 0.9 (0.8-1.0) | .29* |
| Sex, male | 1.7 (1.0-2.7) | .32 |
| ZAP-70 greater than 20% | 4.2 (2.3-7.7) | .02 |
| L/A ratio 1 or greater | 3.9 (2.1-7.2) | .03 |
| OS for stages B and C | ||
| Model 1 including IGVH | ||
| Age | 1.5 (1.2-1.8) | .03* |
| Sex, male | 1.0 (0.5-2.1) | .99 |
| UM IGVH | 7.2 (3.4-15.1) | .01 |
| Model 2 including L/A ratio† | ||
| Age | 1.6 (1.3-2.0) | .05* |
| Sex, male | 0.5 (0.3-1.3) | .46 |
| L/A ratio 1 or greater | 6.8 (3.3-14) | .01 |
Multivariate analyses were done separately for IGVH or ZAP-70 and L/A ratio due to the high concordance between the latter 2 parameters and the former.
P for trend test.
ZAP-70 was not independently associated with disease progression or CLL-related death and was then eliminated in the final Cox model.